On the evening of January 30, BGI disclosed its 2023 annual performance forecast. According to the announcement, the company is expected to achieve operating income of 4.2 billion yuan to 4.5 billion yuan and net profit of 80 million yuan to 110 million yuan in 2023.
During the reporting period, BGI continued to carry out "lean management, quality and efficiency improvement", and effectively improved management efficiency and empowered business development by strengthening internal operation and management, strengthening cost and expense control, and improving human resource efficiency. At the same time, BGI continues to carry out forward-looking layout in the iteration and reserve of clinical application products, strives to improve the technology and market advantages of its main business, and continues to promote the development of its main business, so as to provide a strong guarantee for the long-term sustainable development of the company's business.
The cancer prevention and control business has achieved outstanding results
In the face of the overall pressure on the market demand of the industry, BGI took the initiative to seek changes, continued to take the initiative to strategically adjust the product structure of its main business and the first-chain strategy, and promoted the steady development of its main business. Among them, the revenue of cancer prevention and control has achieved significant year-on-year growth.
In 2023, BGI has made great gains in the field of cancer prevention and control, and a number of products have been approved. In 2023, the company's fecal occult blood detection kit (colloidal gold method) will obtain the medical device registration certificate issued by the Hubei Food and Drug Administration, and the fecal DNA methylation combined detection kit and HPV typing detection products will obtain the medical device registration certificate issued by the State Food and Drug Administration.
BGI's product matrix in the field of tumor prevention and control has been continuously enriched, and the competitiveness of its products has been enhanced, making the company's competitive advantage in this field continue to be solidified. In recent years, BGI has continued to improve its tumor prevention and control service system, making full use of its own platform and the advantages of bioinformatics big data to carry out precise prevention and treatment of various types of tumors, and its comprehensive testing sample volume is in the leading position in the industry.
With the gradual deepening of China's aging society and the improvement of health awareness year by year, the market demand for cancer prevention and control will be gradually released. Based on clinical needs, BGI has carried out product innovation and technology upgrades, which is expected to further empower the scale of cancer prevention and control business.
Channel barriers continue to break through
The gene industry has a difficult "technology + channel" double barrier requirements, and BGI actively deploys overseas on the basis of fully tapping the potential of the local market by virtue of its technical advantages and brand advantages.
As one of the necessary conditions for entering the international market, overseas qualifications are difficult to obtain, and have high standards for the technical level, production process and management system of enterprise products, requiring enterprises to have advanced technology and research and development capabilities.
In 2023, BGI has made a number of progress in obtaining overseas qualifications, including the company's fully automatic medical PCR analysis system PM Easy Lab and its three supporting infectious acid detection kits have obtained market access qualifications from the Thai Food and Drug Administration and Saudi Food and Drug Administration, the Infectious Disease Triple Test Kit has obtained the Australian market access qualification, and the Colotect colorect colorect cancer detection product has obtained the Malaysian market access qualification.
Relying on the public health prevention and control platform and capabilities established in the early stage of overseas business, the company continues to transform into medical testing service capabilities for the whole life cycle of reproductive health, tumor prevention and control, infection prevention and control, chronic disease prevention and control, etc., and actively expands overseas business based on a number of overseas access product qualifications and quality systems that have been reserved.
Specifically, in 2023, BGI will open an independent clinical laboratory jointly established with Tibbiyah of Saudi Arabia, and officially signed a memorandum of cooperation with the Saudi Public Health Authority. In addition, the company has reached a number of cooperation intentions and signed agreements with medical institutions, scientific research institutes and other partners in Thailand, Brazil, Argentina, Chile, Serbia and other countries, which has further promoted the promotion and application of the company's precision medicine technology in the global market.
With rich experience in automation, informatization, modularization and standardization, BGI is committed to improving people's livelihood and health and the development of the life and health industry. At the same time, the company's large-scale population detection technology and screening experience can be better used for the rapid expansion of its main business in overseas fields, which is expected to further boost the company's overall business scale growth.